What this pack is
Exelon Oral is the brand name in this record; rivastigmine hard capsules and oral solution is the generic name. Read both together with the dosage form (oral capsule).
PACK CHECK · MARKET FIRST
Exelon OralGeneric namerivastigmine hard capsules and oral solution
How this medicine works
EMA product information describes rivastigmine as enhancing cholinergic neurotransmission through reversible inhibition of acetylcholinesterase and butyrylcholinesterase. This explains pharmacology; it does not predict an individual's memory change, suitability, onset, capsule count, millilitres or whether dosage forms can be switched.
Read source: Europe ↗Current regulatory record · reviewed 2026-08-28More about its action and precautions →Check the market, names, dosage form and route together
A medicine may use different brand names across markets. Keep the market, brand, generic name, dosage form and route together; one matching field does not prove that two packs are the same or interchangeable.
Open the complete product-identity record
Use these fields when the pack, market name or package image needs closer checking. They are evidence boundaries, not substitution instructions.
- International brand name
- Exelon Oral
- Generic name
- rivastigmine hard capsules and oral solution
- Dosage-form class
- Oral hard capsules: 1.5 mg, 3 mg, 4.5 mg and 6 mg; oral solution: 2 mg/mL (as listed in current EU product information)
- Route
- Oral
- Package-image status
- No exact original-brand package image is shown This is deliberate: do not use a retailer, repackager or another-market image to identify the pack in hand. See why and what to check instead →
No source-verifiable mainland-China trade-name cue has been established for this record. This does not establish whether the medicine exists, is approved or is available in mainland China. Check pack text and current CDE/NMPA records item by item.
FOR EVERYDAY QUESTIONS
After the leaflet, continue with the question you still need to check
What this page can show
This is a source-traceable public record. It helps you read the product identity and its listed source documents; each market still needs its own current record check.
What to bring to the next conversation
Bring the actual pack, the label or prescription, and a complete medicine list when you speak with a pharmacist or clinician.
NEXT SAFE STEP
Choose the next safe check
A question about changing, combining or splitting?Put the exact packs on one list before a pharmacist or prescriber checks the full context.Open the family medicine list →A question about cost, reimbursement or availability?First lock the market, exact presentation and date. Use local official reimbursement, hospital or pharmacy channels for a current answer rather than a web estimate.Open regulator and market-record entry points →Unsure about a pack or a cross-border product?Photo reading can return possible record matches only. Check the actual product against the current regulator record for its market.Identify pack text locally →Saw a recall, approval or procurement headline?Open the original publisher, then match its product, market and date. Do not make a stop or switch decision from a headline.Read primary-source news →
PRODUCT PRESENTATION IDENTITY
Strength, pack and device identity
Package strength is not an individual dose. These fields help identify the exact labelled product; they do not calculate how much, how often, a missed-use action, splitting, switching or conversion.
How to read a score line: ‘scored’ or ‘unscored’ first identifies this labelled presentation. A score line by itself does not permit self-splitting, reducing or changing the product. Only an explicit statement in the current label for this exact presentation, checked with a pharmacist against the prescription, can support any further handling.
6 source-backed strength, pack or device records — open the full list
First match the market, dosage form and labelled amount on the pack in hand. The number of tablets, sachets or devices in a pack is not a personal dose or schedule.
EU · Current EMA EU product information (PDF metadata 9 Feb 2026; checked 28 Aug 2026)
Rivastigmine 1.5 mg per capsule; EU product information lists 28, 56, 112-capsule packs
Source-text identity card: no displayable exact official package image. The fields below come from the cited label and are not a visual authentication result.
- Product code
- EU/1/98/066/001-003
- Form and route
- EXELON rivastigmine hard capsule · oral (label product-identity field)
- Listing review
- Cited public label display reviewed 2026-08-28; actual marketing, stock and availability are not established.
- rivastigmine
- 1.5 mglabelled amount per capsule; not an individual capsule count, frequency, conversion or adjustment instruction
- Labelled appearance
- yellow cap/yellow body; red imprint · hard capsule containing off-white to slightly yellow powder · imprint EXELON 1,5 mgNot applicable to this dosage form
EU · Current EMA EU product information (PDF metadata 9 Feb 2026; checked 28 Aug 2026)
Rivastigmine 3 mg per capsule; EU product information lists 28, 56, 112-capsule packs
Source-text identity card: no displayable exact official package image. The fields below come from the cited label and are not a visual authentication result.
- Product code
- EU/1/98/066/004-006
- Form and route
- EXELON rivastigmine hard capsule · oral (label product-identity field)
- Listing review
- Cited public label display reviewed 2026-08-28; actual marketing, stock and availability are not established.
- rivastigmine
- 3 mglabelled amount per capsule; not an individual capsule count, frequency, conversion or adjustment instruction
- Labelled appearance
- orange cap/orange body; red imprint · hard capsule containing off-white to slightly yellow powder · imprint EXELON 3 mgNot applicable to this dosage form
EU · Current EMA EU product information (PDF metadata 9 Feb 2026; checked 28 Aug 2026)
Rivastigmine 4.5 mg per capsule; EU product information lists 28, 56, 112-capsule packs
Source-text identity card: no displayable exact official package image. The fields below come from the cited label and are not a visual authentication result.
- Product code
- EU/1/98/066/007-009
- Form and route
- EXELON rivastigmine hard capsule · oral (label product-identity field)
- Listing review
- Cited public label display reviewed 2026-08-28; actual marketing, stock and availability are not established.
- rivastigmine
- 4.5 mglabelled amount per capsule; not an individual capsule count, frequency, conversion or adjustment instruction
- Labelled appearance
- red cap/red body; white imprint · hard capsule containing off-white to slightly yellow powder · imprint EXELON 4,5 mgNot applicable to this dosage form
EU · Current EMA EU product information (PDF metadata 9 Feb 2026; checked 28 Aug 2026)
Rivastigmine 6 mg per capsule; EU product information lists 28, 56, 112-capsule packs
Source-text identity card: no displayable exact official package image. The fields below come from the cited label and are not a visual authentication result.
- Product code
- EU/1/98/066/010-012
- Form and route
- EXELON rivastigmine hard capsule · oral (label product-identity field)
- Listing review
- Cited public label display reviewed 2026-08-28; actual marketing, stock and availability are not established.
- rivastigmine
- 6 mglabelled amount per capsule; not an individual capsule count, frequency, conversion or adjustment instruction
- Labelled appearance
- red cap/orange body; red imprint · hard capsule containing off-white to slightly yellow powder · imprint EXELON 6 mgNot applicable to this dosage form
EU · Current EMA EU product information (PDF metadata 9 Feb 2026; checked 28 Aug 2026)
Rivastigmine 2 mg/mL; 50 mL amber-glass bottle with oral dosing syringe
Source-text identity card: no displayable exact official package image. The fields below come from the cited label and are not a visual authentication result.
- Product code
- EU/1/98/066/018
- Form and route
- EXELON rivastigmine oral solution · oral (label product-identity field)
- Listing review
- Cited public label display reviewed 2026-08-28; actual marketing, stock and availability are not established.
- rivastigmine
- 2 mg/mLconcentration per mL; not an individual's millilitres or a self-conversion instruction
- Package
- 50 mL per bottle; oral dosing syringe supplied
- Labelled appearance
- clear yellow solution ·
EU · Current EMA EU product information (PDF metadata 9 Feb 2026; checked 28 Aug 2026)
Rivastigmine 2 mg/mL; 120 mL amber-glass bottle with oral dosing syringe
Source-text identity card: no displayable exact official package image. The fields below come from the cited label and are not a visual authentication result.
- Product code
- EU/1/98/066/013
- Form and route
- EXELON rivastigmine oral solution · oral (label product-identity field)
- Listing review
- Cited public label display reviewed 2026-08-28; actual marketing, stock and availability are not established.
- rivastigmine
- 2 mg/mLconcentration per mL; not an individual's millilitres or a self-conversion instruction
- Package
- 120 mL per bottle; oral dosing syringe supplied
- Labelled appearance
- clear yellow solution ·
PACKAGE-VISUAL STATUS
Current EMA oral-product information and capsule appearance text were reviewed, but no official original-brand package image matching one exact strength and pack was retained, so no package visual is shown
This dossier retains EXELON, rivastigmine, four capsule strengths, the 2 mg/mL oral solution, capsule colours and imprints, oral-solution container and EU authorisation numbers. Current EMA product information provides exact textual identity, but no official original-brand image was retained that can safely be displayed and matched to one dosage form, one strength and one pack. To avoid presenting a retail image, version-uncertain image, another-market image, a patch or another rivastigmine product as the exact oral EXELON appearance, the page withholds package imagery and retains the primary product information for enlarged reading.
LABEL READING · NOT A PRESCRIPTION
EXELON oral label reading: mg per capsule, mg/mL and patch mg/24h are different quantities
Reading level: drug-specific label reading. This record has been expanded around its dosage form or a higher-risk reading question; the current target-market label and professional review still apply.
This module uses current EMA EU product information to check EXELON, rivastigmine, four capsule strengths, the 2 mg/mL oral solution, exact authorisation numbers, appearance text and the dosing syringe. It does not generate an individual's capsule count, millilitres, frequency, titration, missed-use remedy, initiation, stopping, oral-form conversion or oral-to-patch conversion.
- Check the dosage form before the number: 1.5, 3, 4.5 and 6 mg are amounts per capsule; 2 mg/mL is the oral-solution concentration; mg/24h is nominal patch delivery over 24 hours. These quantities cannot be directly divided, added or exchanged.
- EMA product information states that capsules are swallowed whole, and the package text says not to crush or open them. Do not open, pour out, divide or mix capsule contents to obtain a ‘half amount’; check the pack, prescription and pharmacist advice together.
- The oral solution is 2 mg/mL and comes with an oral dosing syringe; 50 mL or 120 mL is the bottle content, not one use. The site does not calculate an individual's millilitres from concentration, bottle size or prescribing text.
- The EMA label describes equal-dose interchange between capsules and oral solution within professional prescribing. This is not permission for public self-conversion. Any change needs a clinician or pharmacist using the exact prescription, actual pack, dosing syringe and interruption history.
- EXELON oral products and EXELON PATCH are different product forms. Do not self-combine, alternate or switch to a patch because they share a brand or rivastigmine. Interruption, missed use, vomiting, diarrhoea, weight loss or marked symptoms after use need the treating team and current product information.
PHARMACOVIGILANCE · OFFICIAL ROUTES
Check safety information in the right market
Start with the public label or product record linked to this dossier, then use the official safety routes below for the market that applies to the medicine in hand.
Match five details before using a safety record
- Brand and generic nameBoth must match the medicine named by the record.
- Dosage form and strengthTablet, capsule, injection, inhaler, patch and eye drop are not interchangeable.
- Market and notice dateA record applies only to the country or region and date it names.
- Lot, pack and manufacturerRecord these only when the official notice specifically names them.
- Current product informationA historical record may have been superseded by the current label.
This checklist only helps organise the right question. It does not create a personal conclusion about stopping, switching, dose, combination or suitability.
This dossier’s product-level source checkEMA · European Union / European Economic Area · Regulatory product record or EU product information · 2026-08-28
This dossier’s publicly accessible product-level route has been checked individually. It does not mean that real-time alerts in every country or region have been searched, or that the medicine has or does not have a current risk.
Markets actually represented by the reviewed product documents
- European Union / European Economic Area · 2
This is a document-coverage summary, not a claim that the medicine is authorised, supplied, interchangeable or actively monitored in every listed market today.
This record’s label or product-record routeEMA: current EU EXELON rivastigmine product information (capsules, oral solution and patches; Feb 2026) ↗Current regulatory record · reviewed 2026-08-28
Other official market or version documents for this record
These are separately reviewed product documents for the same dossier. Their market, date, dosage form and document status must stay attached to each link; they do not establish interchangeability between products, strengths, packs, indications or countries.
- EMA · European Union / European Economic Area · Regulatory product record or EU product information · 2026-08-28EMA: EXELON European public assessment report page (updated 24 Feb 2026) ↗Current regulatory record · reviewed 2026-08-28
This is not a conclusion that the medicine has no risk, warning, recall or newer notice in another market. Start with the checked product-level label above, then use the official market gateways below for the product in hand.
See the reviewed safety-record directory →Global official safety gateways
- NMPA Centre for Drug Reevaluation · Mainland ChinaPrimary NMPA Drug Evaluation Centre gateway for drug-vigilance bulletins, safety notices and adverse-reaction monitoring. Exact products still require checking approval number, dosage form, strength, authorisation holder and notice date item by item.Drug-vigilance bulletins and safety notices ↗reviewed 2026-08-22
- FDA · United StatesPrimary FDA pages for important new safety issues, labelling changes and risk communications.Drug Safety Communications ↗reviewed 2026-08-22
- FDA MedWatch · United StatesU.S. MedWatch safety-information and reporting gateway; a report does not itself establish causality.Safety information and serious-problem reporting ↗reviewed 2026-08-22
- EMA · European Union / European Economic AreaOfficial EU gateway for pharmacovigilance, suspected adverse-reaction reports and PRAC safety assessment.Pharmacovigilance overview and EudraVigilance ↗reviewed 2026-08-22
- MHRA · United KingdomPrimary UK MHRA medicine-safety updates for professionals and the public.Drug Safety Update ↗reviewed 2026-08-22
- PMDA · JapanPMDA’s English official safety gateway; exact products still require checking against the Japanese product page and current documents.Medicine safety information ↗reviewed 2026-08-22
- MFDS · Republic of KoreaMFDS’s primary index for medicine safety letters in the Republic of Korea. The original notices are in Korean and must be read against the named product, dosage form, market and date; they do not automatically apply in another market or decide an individual case.Medicine safety letters ↗reviewed 2026-08-22
- HSA · SingaporeHSA’s public Singapore gateway for suspected adverse-event reporting and medicine-safety information. A report does not itself establish individual causality; exact products still require checking Singapore registration status, dosage form, strength, date and current product information.Adverse-event reporting and medicine-safety information ↗reviewed 2026-08-22
- Health Canada · CanadaHealth Canada’s public MedEffect gateway for medicine and health-product advisories, warnings, recalls, reporting and safety information. Exact products still require checking market, dosage form, strength, notice date and lot item by item.MedEffect Canada: advisories, warnings and recalls ↗reviewed 2026-08-22
- TGA · AustraliaPrimary Australian TGA safety alerts, advisories and monitoring information for therapeutic products.Medicine safety alerts ↗reviewed 2026-08-22
- Swissmedic · SwitzerlandOfficial Swissmedic gateway for pharmacovigilance, signal assessment and suspected adverse-reaction reporting; a report or signal does not itself confirm individual causality.Pharmacovigilance and suspected adverse-reaction reporting ↗reviewed 2026-08-22
- Medsafe · New ZealandNew Zealand Medsafe gateway for public and professional medicine safety communications and archives; older notices may have been superseded by current product information.Medicine safety communications ↗reviewed 2026-08-22
- SAHPRA · South AfricaSAHPRA’s safety-information, alerts and pharmacovigilance gateway for the public and professionals in South Africa. An official alert does not itself mean a product is unsafe in every circumstance; exact products still require checking South African registration status, dosage form, strength, notice date and current product information.Medicine safety information, alerts and pharmacovigilance ↗reviewed 2026-08-22
- WHO · GlobalWHO’s cross-market safety-alert archive; every historical notice must be read against its date, named product and market.Medicine and vaccine safety-alert archive ↗reviewed 2026-08-22
- Anvisa · BrazilAnvisa’s primary Brazilian pharmacovigilance gateway for alerts, bulletins, risk communication and VigiMed reporting. Exact products still require checking Brazilian authorisation status, dosage form, strength and notice date item by item.Pharmacovigilance, alerts and VigiMed ↗reviewed 2026-08-22
This card brings together the medicine-specific product route and 15 market-level official vigilance gateways. It does not mean real-time alerts for this medicine have been searched in every country or region, or that the medicine has a new alert, recall or risk conclusion. Match brand, generic name, dosage form, strength, market and notice date item by item; do not self-stop, switch, increase or reduce use from a headline.
For severe or rapidly worsening symptoms, suspected overdose, a severe allergic reaction, loss of consciousness or another emergency, use local emergency services. Do not wait for an online alert search or change a medicine from this page.
PRIVATE FAMILY LIST
Bring this record into a local medicine list
Only the brand, generic name, dosage form and route are added, and they stay in this browser. Copy strength, label directions, start/stop history and any concern from the actual pack; this tool does not calculate a dose or decide combination, switching or stopping.
Add to the family medicine list →PACK · LABEL · MEDICINE LIST
Six checks for this medicine pack
Use this card to organise questions about Exelon Oral (rivastigmine hard capsules and oral solution). Keep the exact pack, its current label and the full medicine list together.
Identify the exact product
Exelon Oral is the brand in this record and rivastigmine hard capsules and oral solution is the active-ingredient name. Check both with the dosage form (Oral hard capsules: 1.5 mg, 3 mg, 4.5 mg and 6 mg; oral solution: 2 mg/mL (as listed in current EU product information)) and the market on the actual pack.
Read the labelled strength in context
mg, mcg, mg/mL or a percentage describes the labelled amount in one tablet, capsule, measured volume, spray or other unit. It is not an answer to how many units a person should take.
Check before splitting or opening
Before splitting, crushing, chewing or opening anything, find an explicit instruction for this exact product in its current label and ask a pharmacist. A score line or a previous pack is not enough by itself.
Put every product on one list
Include prescriptions, over-the-counter products, eye drops, creams, vitamins, minerals, herbs and supplements. A pharmacist or prescriber needs the whole list before any combination, alternation, switch or stop is considered.
Ask a specific pharmacogenetics question
Ask which medicine, which gene and what clinical decision a result could change. A gene–drug association does not mean broad genetic testing is needed for everyone and must not be used to change treatment without professional review.
Know when to seek urgent help
For a suspected overdose, a severe allergic reaction, fainting or difficulty breathing, use the local emergency or poison-information service now. Do not wait for a website reply or alter several medicines to test what caused it.
This card does not calculate a dose, decide whether medicines can be combined, or replace a clinician or pharmacist. Market-specific current labels and the person's full context still need review.
MARKET DOCUMENTS · READ SEPARATELY
Enlarged market leaflets and regulator documents
Each link retains its own market, date, dosage form and document status. These documents support larger-print reading and item-by-item checking; they do not make products, strengths, packs, indications or use between countries or regions interchangeable.
- EMA: current EU EXELON rivastigmine product information (capsules, oral solution and patches; Feb 2026) ↗Current regulatory record · reviewed 2026-08-28
- EMA: EXELON European public assessment report page (updated 24 Feb 2026) ↗Current regulatory record · reviewed 2026-08-28
HOW IT WORKS · NOT A TREATMENT PLAN
How rivastigmine works: reversible cholinesterase inhibition does not mean reversing the underlying disease
- Mechanism is not a ‘more is better’ rule and cannot justify self-increasing, adding another cholinesterase inhibitor or abrupt stopping.
- The same ingredient delivered by capsule, oral solution or patch still has different product identities, quantity conventions and label handling; shared mechanism does not make the forms self-interchangeable.
- Older people often use several prescriptions, OTC products and supplements. Bring the actual packs, dosing syringe, full medicine list and symptom changes for item-by-item review by a pharmacist or prescriber; the site does not replace individual assessment.
SOURCE EVIDENCE REGISTER
Source evidence map
Every public link is labelled with its market, document status and document type. A historical public record is not a current label, and an official lookup entry is not a product-specific record.
- EMA: EXELON European public assessment report page (updated 24 Feb 2026) ↗Current regulatory record · reviewed 2026-08-28
- EMA: current EU EXELON rivastigmine product information (capsules, oral solution and patches; Feb 2026) ↗Current regulatory record · reviewed 2026-08-28
SOURCE-TRACEABLE ARCHIVE
Exelon Oralrivastigmine hard capsules and oral solution
This page links to public primary-source material for Exelon Oral. The archive is historical or documentary evidence only; it does not by itself establish originator status, product quality, current labelling, availability or sale eligibility.
DOCUMENT TIMELINE
Document timeline
EXELON EU marketing-authorisation node
EMA lists EXELON's EU marketing authorisation as valid from 12 May 1998. This node locates the EU brand record; it is not treated as approval, supply or an originator/generic conclusion for another market.
EMA: EXELON European public assessment report page ↗Current EU product-information version
The current EMA product-information PDF has a modification date of 9 Feb 2026 and separately lists 1.5, 3, 4.5 and 6 mg capsules plus the 2 mg/mL oral solution. The date identifies a document version and does not establish local stock or purchase availability for every presentation.
Primary-source record (open linked document) ↗EMA product page last updated
EMA displays ‘Last updated 24 February 2026’. This dossier keeps the page-update date separate from the product-information date so that a web-maintenance date is not misread as a change in clinical use.
EMA: EXELON European public assessment report page ↗
MARKET SCOPE
Market-record boundary
European Union
Current product information and six exact oral-product identities linkedThe dossier separately records four capsule strengths and two oral-solution bottle sizes, bounded by current EMA EU product information. It does not establish stock, purchase, authentication, individual use or self-directed conversion.
Mainland China, United States, Japan and other markets
Current market record not establishedNo local approval, holder, supply, sale eligibility, originator/generic relationship or interchangeability is inferred from the EU authorisation, EMA trade name, strengths, pack text or shared ingredient.
How to read this record
Read each document in its stated market, date and dosage-form context. A historical record is not a current label and does not support individual medical, substitution or purchasing conclusions.
RECORD FAQ
Record questions
Does 2 mg/mL mean one use must be 2 mg or 1 mL?
No. 2 mg/mL is the concentration per millilitre and identifies the oral-solution product. Individual millilitres require the exact prescription, supplied dosing syringe and professional review; the site does not calculate them.
Can EXELON capsules, oral solution and patches be self-switched from mg numbers alone?
No. Milligrams per capsule, mg/mL and mg/24h use different quantity bases. Conversion text in EMA product information belongs to professional prescribing; any change needs a clinician or pharmacist using the exact product and interruption history.
READ NEXT
Related reading
Evidence status
The listed links are public sources selected for traceability. They must be rechecked against the current target-market record before any use beyond reading and research.